These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 8291917

  • 1. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
    Seguchi T, Nakano E, Miki T, Kondoh M, Nishimura K, Nakamura N, Okuyama A.
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
    [Abstract] [Full Text] [Related]

  • 2. [Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
    Hashimura T, Okumura K, Akao T, Nakagawa T.
    Hinyokika Kiyo; 1991 Jul; 37(7):685-8. PubMed ID: 1927767
    [Abstract] [Full Text] [Related]

  • 3. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M, Kotake T.
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [Abstract] [Full Text] [Related]

  • 4. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Kume T, Masu C, Ishino T, Nakatsu H.
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [Abstract] [Full Text] [Related]

  • 5. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
    Bellmunt Molins J, Ribas A, Albanell J, Lorente Garín JA, de Torres Mateos JA, Morote Robles J, López Palacios MA, Banús Gassol JM, Casado Cobo S, Eres N, Solé Calvo LA.
    Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
    [Abstract] [Full Text] [Related]

  • 6. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
    Fukuda H, Mitsumori K, Minagawa S, Kumazawa T, Tadachi K, Iinuma M, Satoh S, Satoh K, Habuchi T, Kato T.
    Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
    [Abstract] [Full Text] [Related]

  • 7. [Early clinical result of modified M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of renal pelvis and ureter].
    Shishido S, Hayakawa M, Higa I, Koyama Y, Hatano T, Osawa A.
    Hinyokika Kiyo; 1990 Apr; 36(4):401-5. PubMed ID: 2378303
    [Abstract] [Full Text] [Related]

  • 8. [Clinical evaluation of intra-arterial methotrexate, vinblastine, doxorubicin and cis-platinum for bladder cancer].
    Tanabe T, Tanaka G, Okutani T, Nishimoto K, Kawashita E, Yoneda K, Fujii M, Shiraishi T.
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2207-11. PubMed ID: 1444487
    [Abstract] [Full Text] [Related]

  • 9. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A.
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

  • 12. [Chemotherapy of metastatic cancer of the bladder. Apropos of 50 patients treated with M-VAC].
    Beuzeboc P, Dhote R, Thiounn N, Flam T, Zerbib M, Debré B, Pouillart P.
    Cancer Radiother; 1998 Apr; 2 Suppl 1():92s-96s. PubMed ID: 9749087
    [Abstract] [Full Text] [Related]

  • 13. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    Ann Urol (Paris); 1993 Apr; 27(1):51-7. PubMed ID: 7682388
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Nakatsu H, Kume T, Kodama M, Masu C.
    Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N, Arima K, Sugimura Y.
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
    Mikami K, Nakagawa S, Takada H, Ebisui K, Sugimoto K, Watanabe H, Maegawa M, Nakao M.
    Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
    [Abstract] [Full Text] [Related]

  • 20. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H.
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.